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Purpose

 his study aimed to assess the optimal tumor diameter for predicting lymphatic metastasis and
T
to determine intraoperatively the need for lymph node dissection in patients with endometrioid
endometrial cancer.

Methods

 ilitary beneficiaries diagnosed with stage I–III endometrioid endometrial cancer during 2003–2016
M
who had at least 7 pelvic and/or paraaortic lymph nodes removed during the time of hysterectomy
were studied. Tumor diameter was compared against the presence of positive nodes, using the prior
models of 20 mm (ie, Mayo model) and 50 mm (ie, Milwaukee model), to determine the false-negative
rate of each threshold. A separate analysis was completed to determine the optimal diameter for our
population. Receiver operating characteristic curve analysis models of tumor diameter were evaluated
for model fit and predictive power of lymph node involvement.

Results

 f the 1224 patients with endometrioid endometrial cancer included, 13% (n=160) had positive lymph
O
node involvement. Tumor sizes ranged from 1 mm to 100 mm. In contrast to Mayo and Milwaukee
models (ie, Mayo, Milwaukee), the optimal tumor diameter independent of myometrial invasion and
grade of tumor to predict lymph node metastasis was found to be 35 mm.

Conclusions

 ndometrioid endometrial cancer tumor diameter of 35 mm was found to be the optimal threshold for
E
lymphadenectomy when the operating surgeon has no knowledge of tumor invasion. (J Patient Cent
Res Rev. 2020;7:323-328.)
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U

terine cancer is the fourth most common form of
female cancer in the United States and remains
the most commonly diagnosed gynecologic
cancer, accounting for 57,368 diagnoses in 2017 and
10,994 deaths.1 According to the National Institutes of
Health’s Surveillance, Epidemiology, and End Results
Program database, 65,620 new cases of uterine cancer
are expected by the conclusion of 2020, affecting
27.8 per 100,000 women and comprising 3.6% of all
new cancer case diagnoses. Current lifetime risk is
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estimated to be 3.1%.2 In 2017, there were an estimated
793,846 women living with uterine cancer in the United
States. Worldwide, uterine cancer continues to be the
most common gynecologic cancer and the eighth most
common cancer.3
Due to its prevalence, appropriate surgical management is
crucial for optimal prognosis. Currently, the standard of
care includes total hysterectomy and bilateral salpingooophorectomy with complete lymphadenectomy
for all patients at risk of lymphatic dissemination.4,5
Since 1988, the International Federation of Obstetrics
and Gynecology (FIGO) has recommended surgical
staging for endometrial cancer patients, as lymph node
involvement is an important prognostic indicator.6,7
Complete lymphadenectomy, however, has significant
morbidity and no change in mortality rates for low-
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risk patients.5,7-11 There is also considerable variation in
type of lymphadenectomy that can be performed. The
extent of lymph node assessment for what is considered
optimal patient management has varied from sentinel
node mapping to complete pelvic and paraaortic
lymphadenectomy.
Because of this variation, disease management and
risk scoring models were developed to personalize
intraoperative or postoperative care by predicting the
probability of a clinical event or outcome.12,13 Utilizing
these models to identify low-risk patients and avoid
lymphadenectomy to decrease morbidity was the goal. The
definition of a low-risk patient varies, with the currently
used risk scoring models including tumor variables that
are not always readily available intraoperatively. Hence,
these models have had little significance on standardizing
intraoperative surgical management.
The use of sentinel lymph node mapping by gynecologic
oncologists is increasingly accepted in community
practice for low- to intermediate-risk patients, but details
about its implementation and what to do with high-risk
patients remain controversial.14-16 Use of sentinel nodes
as a solution is limited by the technical reality that the
injections for mapping must be performed prior to
uterine removal. If a previously undiagnosed tumor is
discovered intraoperatively after uterine removal, other
strategies must be used to determine lymph node status
in low- and intermediate-risk patients. Furthermore,
endometrial cancer surgeries may or may not be
performed by gynecologic oncologists.17 Given these
realities of undiagnosed cancer and possible sentinel
lymph node mapping failure, there will always be a need
for intraoperative risk assessment that relies on easily
obtained tumor-related information.
The most commonly used criteria for predicting
individualized risk of lymphatic dissemination in patients
with endometrioid endometrial cancer (EEC), a type
of uterine cancer, is based on a study by Mayo Clinic
(Rochester, MN).10 The Mayo model, first published
in 2000, includes presence of lymphovascular space
invasion (LVSI), myometrial invasion of >50%, FIGO
grade I or II, primary tumor diameter of ≥2 cm (ie, ≥20
mm), and cervical stromal invasion. In the Mayo model,
a tumor diameter greater than 20 mm confers a 5-fold
increased risk of lymphatic dissemination. Subsequently,
elimination of tumor diameter from risk stratification
resulted in an overestimation of the risk of lymphatic
dissemination.13 However, since tumor diameter has
not been an independent predictor of lymph node
metastasis, national and international guidelines for
management of EEC have not emphasized its usefulness
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for intraoperative decisions.18 Regardless of retrospective
analysis of tumor-related risk factors for lymph node
metastasis, tumor diameter remains an easily collected
piece of intraoperative information available to the
surgeon, whereas LVSI status, grade, and sometimes
even myometrial invasion are not immediately available.
Sentinel lymph node dye injection must be performed
prior to uterine removal and before many of the tumorrelated risk factors are known.
A retrospective study encompassing data from the 15-hospital
Aurora Health Care health system (Milwaukee, WI) on
727 patients with cancer was performed by Cox Bauer et
al and published in 2016.13 Their study confirmed tumor
diameter was an important predictor of lymphatic metastasis
in patients diagnosed with early-stage endometrial cancer
and indicated that predictability of lymphatic dissemination
might be improved by increasing the tumor diameter cutoff
from the previously proposed Mayo model of 20 mm to
50 mm and lowering the myometrial invasion cutoff from
50% to 33% (ie, the Milwaukee model). The data revealed a
3.1% increase in odds of lymphatic dissemination per 1-mm
increase in tumor diameter, a 3.7% increase in lymphatic
dissemination per 1% increase in myometrial invasion,
and an increase in overall sensitivity on determining risk of
lymphatic dissemination using the new criteria. These results
suggested that tumor diameter can function as an alternative
predictor of lymphatic metastasis at hospitals that do not
have pathology readily available to evaluate myometrial
invasion or when the intraoperative analysis is unclear.
Several studies have demonstrated the significance of
tumor diameter as an important prognostic indicator,
though most use the threshold value of 20 mm from the
NCCN guidelines.14,19 Our goal for the study presented
herein is to examine if tumor diameter alone can be
utilized to predict lymph node dissemination and evaluate
if there is an optimal tumor size for predicting lymphatic
spread. We also aim to provide external validity of the
Milwaukee model by evaluating tumor diameter and
lymph node metastasis in the Military Health System
(Falls Church, VA), which provides a larger, more
geographically diverse, variable patient population.
Determining whether the optimal tumor size of 20 mm
versus 50 mm for low-risk patients with EEC in this
population is consistent with prior models is the primary
goal, with the secondary objective of exploring whether
there is a more optimal tumor diameter to best predict
lymphatic involvement.

METHODS

A retrospective analysis of adult patients diagnosed
with EEC was completed. Patients were 18 years of age
and older, seen within the U.S. Department of Defense
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Military Health System from January 2003 to May
2016, and registered with the Automated Central Tumor
Registry (ACTUR). The use of pelvic and/or paraaortic
lymphadenectomy during hysterectomy was the standard
for all EEC cases during this period. Patient inclusion
was based on final pathologic diagnosis of endometrioid
histology; patients with less than 7 lymph nodes removed,
nonendometrioid histology, stage IV classification, and/
or missing information regarding lymph node status
were excluded from the study. Patient demographics
as well as tumor and treatment characteristics were
identified from the U.S. Department of Defense cancer
registry. The Brooke Army Medical Center (San Antonio,
TX) institutional review board approved the study
(#C.2017.092n).
Categorical data were summarized by percentages and
analyzed using the chi-squared test or Fisher’s exact test,
whichever was most appropriate. Means and standard
deviations (SD) or medians were used as summary
statistics for continuous variables. Logistic regression
was performed to determine the predictive qualities of
various factors associated with positive nodes. Unlike
the Mayo and Milwaukee models, this model only uses
tumor diameter and does not include information about
LVSI or myometrial invasion. Odds ratios, along with
their corresponding Wald’s 95% confidence intervals,
were reported.
Receiver operating characteristic (ROC) analysis also
was performed to determine the predictive quality of
the model. Finally, ROC curves were used to determine
which cutoffs optimized sensitivity and specificity of
predicting a positive node. Significance for results was
established when P-values were less than 0.05. All
statistical analysis was performed using SPSS Statistics
V22.0 software (IBM Corporation).

RESULTS

A total of 1300 patients diagnosed with EEC via surgical
pathology were found in the ACTUR database from

2003 to 2016. After patients without at least 7 lymph
nodes (61 patients) and stage IV patients were removed,
a total of 1224 patients remained. Of those 1224, 160
patients had positive lymph node status (13.1%), 800
patients had a tumor size of ≥20 mm in size (65.4%),
and 253 had a tumor size of ≥50 mm (20.7%). Patients
ranged in age from 18 to 90 years, with the majority in
the 50–65-year-old bracket. The mean age was 54 years
(SD: 13 years); 67% of the population was White nonHispanic, 9% was African American, 5% was Filipino,
2% was Pacific Islander, and 1% was Japanese, Korean,
or Micronesian.
The mean tumor size was 39 mm (SD: 78 mm). The
presence of LVSI was reported in 588 (48%) of the 1224
patients with EEC analyzed, with 132 (22%) of those
588 patients found LVSI-positive. Unlike the Mayo and
Milwaukee models, this model only used tumor diameter
and did not include information about myometrial
invasion or tumor grade.
Individual ROC curves were analyzed to determine the
best fit, both as a continuous variable and by using the
20-mm and 50-mm tumor diameter cutoffs from the
Mayo and Milwaukee models (Table 1; Figures 1–3).
Sensitivity and specificity at 20 mm were 81.9% and
37.1%, respectively. Sensitivity and specificity at 50 mm
were 82.1% and 39.4%, respectively (Table 2). Positive
predictive value at 20 mm was 16.4% and at 50 mm was
24.9%. Negative predictive value at 20 mm was 92.9%
and at 50 mm was 90.0%. The false-negative rate was
6.8% for 20 mm and 10.0% for 50 mm.
The continuous ROC curve optimized sensitivity and
specificity with an ideal tumor size of 35 mm for this
patient population, which falls between the two values
proposed by the Mayo and Milwaukee models. A tumor
diameter cutoff of 35 mm resulted in sensitivity of 65.6%
and specificity of 63.0%, positive and negative predictive
values of 21.0% and 92.4%, respectively, and a falsenegative rate of 7.6% (Table 2).

Table 1. Comparison of Risk Assessment Models Using Tumor Diameter Only*
Model

R2 (U)

AICc

BIC

AUC

Tumor diameter (continuous)

0.0046

948.9

959.1

0.671

Tumor diameter ≥ 20 mm

0.0256

928.9

939.1

0.595

Tumor diameter ≥ 50 mm

0.0362

918.9

929.1

0.608

*Evaluation of the 20-mm and 50-mm cutoffs in our patient population confirmed that the 50-mm model performed better.
AICc, Akaike information criterion with correction; AUC, area under the curve; BIC, Bayesian information criterion.
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Figure 1. Lymphatic dissemination models containing
tumor diameter only were analyzed using receiver
operating characteristic (ROC) curves. Shown here is
the ROC curve (black) and iso-performance line (yellow)
for a model containing 20-mm tumor diameter only.

Figure 2. Receiver operating characteristic curve for
a lymphatic dissemination model containing 50-mm
tumor diameter only.

DISCUSSION

Recently, Cox Bauer et al proposed the Milwaukee risk
model as an alternative to the long-used Mayo criteria
for patients with EEC, citing the former’s increased
sensitivity and specificity in predicting lymph nodepositive status with cutoffs for tumor diameter of ≥50
mm and myometrial invasion of >33%.13 That study
highlighted the importance of tumor diameter in risk
assessment, even more so than the extent of myometrial
invasion, once tumor diameter was examined as both
continuous and categorical variables. Our study sought
to determine external validity of the Milwaukee model
and analyze tumor diameter as a continuous variable in
a nationwide military population. In Milwaukee model
data, there was a 3.1% increased odds of lymph node
metastasis for every 1-mm increase in tumor diameter.
This was consistent with the collected LVSI and depth of
invasion risk of lymph node metastasis data collected in
our study population.
As myometrial invasion was not consistently available
throughout the ACTUR database, the main focus of our
study became tumor diameter and whether the Milwaukee
model could be recreated solely using tumor diameter as
a continuous variable. The ACTUR data validated the
Milwaukee model’s suggestion that, compared to 20 mm,
50 mm serves as a better cutoff threshold, with a superior
positive predictive value (24.9% vs 16.4%) and a small
effect on the false-negative rate (10.0% for 50 mm vs
326 JPCRR • Volume 7, Issue 4 • Fall 2020

Figure 3. Receiver operating characteristic curve for
continuous tumor diameter, which revealed a 35-mm
cutoff as having the most optimal sensitivity and
specificity to predict risk of lymph node involvement.

6.8% for 20 mm). Of further interest, when ACTUR
data were used to analyze the optimal tumor diameter to
maximize sensitivity and specificity, 35 mm was noted
to be the optimal threshold, with positive (21.0%) and
negative (92.4%) predictive values falling between the
two previous models and a false-negative rate of 7.6%.
Original Research

Table 2. Sensitivity and Specificity of Three Tumor
Diameter Models
Tumor diameter

Specificity

Sensitivity

35 mm

0.6297

0.6563

20 mm

0.3712

0.8188

50 mm

0.8214

0.3938

Ideal risk stratification for spread of EEC requires the
presence of three key pieces of information: LVSI,
percentage of myometrial invasion, and tumor diameter.
However, sometimes tumor diameter is the only piece
of information available to the surgeon. We propose
that a tumor diameter of 35 mm, rather than the 20 mm
used in the Mayo model or the 50 mm suggested by the
Milwaukee model, should serve as the cutoff value for
this risk factor. By increasing the level of tumor size from
Mayo’s criteria, our proposed model would prevent an
additional number of unnecessary lymphadenectomies.
Importantly, this less comprehensive model would be
intended for intraoperative use when a patient’s sentinel
lymph nodes cannot be identified, when a tumor was not
recognized prior to surgery, or when frozen pathology is
inconclusive or not available. While we hope that these
situations are rare, it is our opinion this tumor diameter
model can be utilized to achieve reasonable outcomes.
EEC is one of the most common female cancers, and our
model becomes valuable when gross evidence of tumor
is found in patients during the aforedescribed situations.
Tumor qualities that are most predictive of lymph node
dissection — LVSI, grade, and depth of invasion —
are not readily available at all times in all institutions,
nor in patients for whom attempted identification of
a sentinel lymph node fails. In rural or community
settings with limited pathology support, we suggest that
tumor diameter alone is a potent predictor of lymphatic
metastasis, thereby allowing an easy method to determine
the extent of lymph node dissection needed.
As sentinel lymph node dissection becomes more routine,
tumor diameter models may become less important.
However, sentinel lymph node mapping failures do occur,
even at centers where they are commonly performed.
Depending on technique, identification of bilateral
lymph nodes is reported to range from 66% to 97%.20,21
At this time, National Comprehensive Cancer Network
guidelines recommend a full lymph node dissection
should sentinel node mapping fail.16 A scoring system
based on tumor size may help avoid morbidity in this
subset of patients. Furthermore, although patients with
Original Research

endometrial intraepithelial neoplasia (EIN) have as high
as a 43% risk of concurrent endometrial cancer, there
is lack of consensus if sentinel lymph node mapping
or frozen section should be performed in patients with
EIN.22 Thus, for these patients, examination of the uterus
for tumor and measurement of tumor diameter could be
used to predict the risk of lymphatic spread and need for
lymphadenectomy. Our model can be used to determine
how to proceed in patients who have unpredicted gross
tumor on intraoperative uterine inspection.
Limitations

Limitations of the study include absence of myometrial
invasion and LVSI information for a large subset of the
patient cohort. Data were reported to a database and
then retrieved for this study; as such, missing data from
multiple records was noted. This approach limited our
ability to reconstruct the Mayo and Milwaukee models
completely using our dataset.

CONCLUSIONS

Patients with endometrioid endometrial cancer registered
in the Military Health System cancer database (ACTUR)
were used as a validation population for the Milwaukee
model of metastatic risk assessment, which uses tumor
diameter to predict presence of lymph node metastasis
and suggests that tumor diameter alone can be used to
predict lymph node involvement of disease. Our study
validated the Milwaukee model’s 50-mm threshold for
tumor diameter but also found that, when relying on
tumor size only (a clinically relevant scenario), forgoing
lymph node dissection in endometrioid endometrial
tumors less than 35 mm in diameter resulted in an
acceptable false-negative rate.
Patient-Friendly Recap
• Assessing risk in patients with uterine cancer based
on tumor size would allow clinicians to determine
whether or not a lymphadenectomy is needed
without taking a frozen section or relying on sentinel
lymph node identification.
• The authors analyzed a large, national patient
population to validate if tumor size alone can
adequately assess patient risk, especially in clinical
scenarios where lymph node mapping fails or is
unavailable.
• In addition to verifying tumor diameter as a reliable
standalone risk factor, they identified 35 mm as the
optimal cutoff for sufficiently assessing patient risk
while avoiding surgery.
• Further validation of this 35-mm tumor diameter
threshold is needed.
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